Search results for " personalized medicine"

showing 10 items of 23 documents

Anakinra drug retention rate and predictive factors of long-term response in systemic juvenile idiopathic arthritis and adult onset still disease

2019

Background and Objective: Only a few studies have reported long-term efficacy of interleukin (IL)-1 inhibition in systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still disease (AOSD). Herein we report on the effectiveness of anakinra (ANA), expressed in terms of drug retention rate (DRR), and evaluate the predictive factors of drug survival in a cohort of patients with sJIA and AOSD. Patients and Methods: This is a multicenter study reviewing retrospectively the medical records from 61 patients with sJIA and 76 with AOSD, all treated with ANA in 25 Italian tertiary referral centers. Results: The cumulative retention rate of ANA at 12-, 24-, 48-, and 60-month of follow-up was 7…

0301 basic medicineAdult onset Still diseasemedicine.medical_specialtyArthritisStill DiseaseAdult onset Still disease; Anakinra; Drug retention rate; Innovative biotechnologies; Interleukin 1-beta; Personalized medicine; Systemic juvenile idiopathic arthritis03 medical and health sciences0302 clinical medicineSettore MED/38 - Pediatria Generale E Specialisticaanakinra interleukin 1-beta innovative biotechnologies drug retention rate systemic juvenile idiopathic arthritis adult onset Still disease personalized medicineSystemic juvenile idiopathic arthritisInternal medicinemedicinePharmacology (medical)Adverse effectOriginal ResearchPharmacologyAnakinrabusiness.industryHazard ratiolcsh:RM1-950Innovative biotechnologiesmedicine.diseaseDrug retention ratePersonalized medicineConfidence intervalAdult onset Still disease Anakinra Drug retention rate Innovative biotechnologies Interleukin 1-beta Personalized medicine Systemic juvenile idiopathic arthritisDiscontinuation030104 developmental biologylcsh:Therapeutics. PharmacologyAnakinraInnovative biotechnologie030220 oncology & carcinogenesisCohortInterleukin 1-betabusinessmedicine.drug
researchProduct

NF-κB Is a Potential Molecular Drug Target in Triple-Negative Breast Cancers.

2017

Breast cancer continues to cause significant burden in global health morbidity and mortality. Triple-negative breast cancers (TNBCs) are highly aggressive with poor prognosis and are characterized by lack of expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor (Her-2). TNBCs are often resistant to cytotoxic chemotherapy and pose major difficulty in achieving personalized medicine due to their molecular heterogeneity. There is increasing evidence that the aberrant activation of nuclear factor (NF)-κB signaling is a frequent characteristic of TNBCs. We evaluated the effects of different potential NF-κB inhibitors, such as bisindolylmaleimide I (BI…

0301 basic medicineCurcuminEstrogen receptorTriple Negative Breast NeoplasmsPharmacologydiagnostics drug targets NF-kB signaling personalized medicine triple-negative breast cancerBiochemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBreast cancerCell Line TumorMG132Progesterone receptorGeneticsmedicineGene silencingHumansPrecision MedicineMolecular BiologyTriple-negative breast cancerbusiness.industryCyclohexanonesNF-kappa BCancermedicine.disease030104 developmental biologychemistry030220 oncology & carcinogenesisBenzamidesProteasome inhibitorCancer researchMolecular MedicineFemalebusinessBiotechnologymedicine.drugSignal TransductionOmics : a journal of integrative biology
researchProduct

Inherent and toxicant-provoked reduction in DNA repair capacity: A key mechanism for personalized risk assessment, cancer prevention and intervention…

2018

Abstract Genomic investigations reveal novel evidence which indicates that genetic predisposition and inherent drug response are key factors for development of cancer and for poor response to therapy. However, mechanisms for these outcomes and interactions with environmental factors have not been well-characterized. Therefore, cancer risk, prevention, intervention and prognosis determinations have still mainly been based on population, rather than on individualized, evaluations. The objective of this review was to demonstrate that a key mechanism which contributes to the determination is inherent and/or toxicant-provoked reduction in DNA repair capacity. In addition, functional and quantita…

0301 basic medicineDNA repairCarcinogenesisPopulationDNA repairBioinformaticsRisk AssessmentHazardous Substances03 medical and health sciencesCarcinogenesis DNA methylation DNA repair microRNA Personalized medicine Precision medicine Public Health Environmental and Occupational Health0302 clinical medicineNeoplasmsMedicineAnimalsHumansEpigeneticsLymphocyteseducationeducation.field_of_studyCancer preventionDNA methylationmicroRNAbusiness.industryMechanism (biology)Precision medicineEnvironmental and Occupational HealthPublic Health Environmental and Occupational HealthComputational BiologyPrecision medicinePersonalized medicine030104 developmental biology030220 oncology & carcinogenesisDNA methylationBiological AssayPersonalized medicinePublic HealthbusinessDNA Damage
researchProduct

Circulating biomarkers in osteosarcoma: new translational tools for diagnosis and treatment.

2017

Osteosarcoma (OS) is a rare primary malignant bone tumour arising from primitive bone-forming mesenchymal cells, with high incidence in children and young adults, accounting for approximately 60% of all malignant bone tumours. Currently, long-term disease-free survival can be achieved by surgical treatment plus chemotherapy in approximately 60% of patients with localized extremity disease, and in 20-30% of patients with metastatic lung or bone disease. Diagnosis of primary lesions and recurrences is achieved by using radiological investigations and standard tissue biopsy, the latter being costly, painful and hardly repeatable for patients. Therefore, despite some recent advances, novel biom…

0301 basic medicineOncologymedicine.medical_specialtyBone diseasemedicine.medical_treatmentDiseaseReviewBiomarkers; Blood serum; Liquid biopsy; Osteosarcoma; Personalized medicine; Oncology03 medical and health sciences0302 clinical medicineBlood serumInternal medicineosteosarcomamedicineLiquid biopsyChemotherapyliquid biopsybusiness.industrybiomarkersBiomarkerpersonalized medicinemedicine.disease3. Good health030104 developmental biologyblood serumOncology030220 oncology & carcinogenesisOsteosarcomaCancer biomarkersPersonalized medicinebusinessOncotarget
researchProduct

Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome-Therapeutic Outcome and Predictors of Response:…

2021

Objective: To describe the role of biotechnological therapies in patients with tumor necrosis factor receptor associated periodic syndrome (TRAPS) and to identify any predictor of complete response.Methods: Clinical, laboratory, and therapeutic data from 44 Caucasian TRAPS patients treated with biologic agents were retrospectively collected in 16 Italian tertiary Centers.Results: A total of 55 biological courses with anakinra (n = 26), canakinumab (n = 16), anti-TNF-α agents (n = 10), and tocilizumab (n = 3) were analyzed. A complete response was observed in 41 (74.5%) cases, a partial response in 9 (16.4%) cases and a treatment failure in 5 (9.1%) cases. The frequency of TRAPS exacerbation…

0301 basic medicinemedicine.medical_specialtyMedicine (General)Settore MED/16 - REUMATOLOGIAmedicine.drug_classtumor necrosis factor inhibitorsbiologic therapy interleukin-1 inhibitors personalized medicine tocilizumab tumor necrosis factor inhibitors tumor necrosis factor receptor-associated periodic syndromeinterleukin-1 inhibitorsGastroenterology03 medical and health scienceschemistry.chemical_compoundtocilizumab0302 clinical medicineTocilizumabR5-920Internal medicinemedicinebiologic therapyAdverse effecttumor necrosis factor receptor-associated periodic syndromeOriginal Research030203 arthritis & rheumatologyAnakinraProteinuriabiologymedicine.diagnostic_testbusiness.industryC-reactive proteinGeneral MedicineTumor necrosis factor receptor associated periodic syndromepersonalized medicineCanakinumab030104 developmental biologychemistryErythrocyte sedimentation ratebiology.proteinAutoinflammationCorticosteroidMedicinemedicine.symptombusinessmedicine.drugbiologic therapy; interleukin-1 inhibitors; personalized medicine; tocilizumab; tumor necrosis factor inhibitors; tumor necrosis factor receptor-associated periodic syndrome
researchProduct

Long-term evaluation of quality of life and gastrointestinal well-being after segmental colo-rectal resection for deep infiltrating endometriosis (EN…

2019

Purposes: The primary objective is to assess the long-term quality of life (QoL) and gastrointestinal well-being in patients with endometriosis (DIE) who underwent segmental resection (SR), through specific questionnaires focused on endometriosis and specific gastrointestinal evaluation. The secondary objectives are represented by the evaluation of peri-operative and post-operative outcomes of the procedure. Methods: This observational cohort study ENDO-RESECT (ClinicalTrials.gov ID: NCT03824054) reports all clinical data about women who underwent SR for DIE between October 2005 and November 2017. In the part of the study dedicated to the QoL assessment, the questionnaires adopted were the …

AdultQuality of lifemedicine.medical_specialtyAbdominal painConstipationAdolescentGastrointestinal DiseasesEndometriosisEndometriosisSegmental colo-rectal resectionHospital Anxiety and Depression ScaleGastrointestinal symptomsCohort StudiesYoung AdultPostoperative ComplicationsQuality of lifePregnancySurveys and QuestionnairesInternal medicineGastrointestinal symptommedicineHumansDeep infiltrating endometriosis; Gastrointestinal symptoms; Intestinal endometriosis; Personalized medicine; Quality of life; Segmental colo-rectal resection; Adolescent; Adult; Cohort Studies; Colorectal Neoplasms; Endometriosis; Female; Gastrointestinal Diseases; Humans; Middle Aged; Postoperative Complications; Pregnancy; Quality of Life; Surveys and Questionnaires; Treatment Outcome; Young Adultbusiness.industryIntestinal endometriosiObstetrics and GynecologyGeneral MedicineMiddle Agedmedicine.diseasePersonalized medicineDeep infiltrating endometriosiTreatment OutcomeSettore MED/40 - GINECOLOGIA E OSTETRICIADeep infiltrating endometriosisDeep infiltrating endometriosis; Intestinal endometriosis; Segmental colo-rectal resection; Quality of life; Gastrointestinal symptoms; Personalized medicineDefecationFemaleIntestinal endometriosisSegmental resectionmedicine.symptomColorectal NeoplasmsbusinessCohort study
researchProduct

Personalized medicine for allergy treatment: Allergen immunotherapy still a unique and unmatched model

2021

International audience; The introduction of personalized medicine (PM) has been a milestone in the history of medical therapy, because it has revolutionized the previous approach of treating the disease with that of treating the patient. It is known today that diseases can occur in different genetic variants, making specific treatments of proven efficacy necessary for a given endotype. Allergic diseases are particularly suitable for PM, because they meet the therapeutic success requirements, including a known molecular mechanism of the disease, a diagnostic tool for such disease, and a treatment blocking the mechanism. The stakes of PM in allergic patients are molecular diagnostics, to dete…

Allergen immunotherapyEndotypeMESH: AllergensMESH: HypersensitivityImmunologyDiseaseBioinformaticsMESH: Precision Medicine03 medical and health sciences0302 clinical medicinemolecular diagnosisHypersensitivityImmunology and AllergyMedicineHumansPrecision MedicineMESH: Desensitization Immunologic[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/AllergologyMESH: Humansbusiness.industryMechanism (biology)MESH: GenomicsGenomicspersonalized medicineAllergenstreatable traitsMolecular diagnosticsOmics3. Good healthBiomarker (cell)omicsallergen immunotherapy; molecular diagnosis; omics; personalized medicine; treatable traits030228 respiratory systemDesensitization Immunologicallergen immunotherapyPersonalized medicinebusiness[SDV.IMM.ALL] Life Sciences [q-bio]/Immunology/Allergology030215 immunology
researchProduct

Network reconstruction for trans acting genetic loci using multi-omics data and prior information.

2022

Background: Molecular measurements of the genome, the transcriptome, and the epigenome, often termed multi-omics data, provide an in-depth view on biological systems and their integration is crucial for gaining insights in complex regulatory processes. These data can be used to explain disease related genetic variants by linking them to intermediate molecular traits (quantitative trait loci, QTL). Molecular networks regulating cellular processes leave footprints in QTL results as so-called trans-QTL hotspots. Reconstructing these networks is a complex endeavor and use of biological prior information can improve network inference. However, previous efforts were limited in the types of priors…

Data Integrationeducation.field_of_studyComputer scienceScale (chemistry)Bayesian probabilityPopulationQuantitative Trait LociBiological databaseInferenceData Integration ; Machine Learning ; Multi-omics ; Network Inference ; Personalized Medicine ; Prior Information ; Simulation ; Systems BiologyComputational biologyQuantitative trait locusReplication (computing)Machine LearningPrior probabilityCohortGeneticsMolecular MedicineHumans:Medicine [Science]Gene Regulatory NetworkseducationTranscriptomeMolecular BiologyGenetics (clinical)Genome medicine
researchProduct

Impact of reslizumab on outcomes of severe asthmatic patients: current perspectives.

2018

Approximately 5%-10% of asthmatics suffer from severe asthma. New biological treatments represent a great opportunity to reduce asthma burden and to improve asthma patients' lives. Reslizumab will soon be available in several European countries. This anti-IL-5 IgG4/kappa monoclonal antibody, administered intravenously at a dose of 3 mg/kg over 20-50 minutes every 4 weeks, has been shown to be safe and effective in patients with 400 eosinophils/mu L or more in their peripheral blood. The clinical effects in reducing asthma exacerbations and in improving the quality of life and lung function are clear, but further research is needed to determine the best biological compound for a specific clu…

Drugmedicine.medical_specialtymedia_common.quotation_subjectReview030204 cardiovascular system & hematologySettore MED/10 - Malattie Dell'Apparato Respiratoriopatient-reported outcomeasthma; patient-reported outcomes; personalized medicine; reslizumabPathogenesis030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineReslizumabInternal medicinemedicineAsthmatic patientPathologicalAsthmamedia_commonbusiness.industrypersonalized medicineasthmamedicine.diseasereslizumabpatient-reported outcomesPersonalized medicinebusinessMepolizumabmedicine.drugPatient related outcome measures
researchProduct

Novel LDL-cholesterol lowering therapies: A step forward a personalized medicine

2023

Internal MedicineLDL personalized medicine
researchProduct